secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001558370-24-016182
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path outlines obesity program for BP1001-A; discontinues BP1002 Phase 1 trial
--------------------------------------------------------------------------------

- BP1001-A aims to treat obesity in Type 2 diabetes by downregulating Grb2 to enhance insulin signaling.
- IND-enabling testing for BP1001-A expected in Q4 2024; preclinical studies ongoing.
- Discontinues Phase 1 study of BP1002 for lymphoma/CLL due to enrollment challenges.
- Company reallocates resources to metabolic program from oncology pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024016182/0001558370-24-016182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024016182/bpth-20241211x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer